{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:07:48Z","timestamp":1780700868178,"version":"3.54.1"},"reference-count":52,"publisher":"Medknow","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi J Kidney Dis Transpl"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/1319-2442.194583","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T11:19:07Z","timestamp":1483960747000},"page":"1103","source":"Crossref","is-referenced-by-count":6,"title":["Renin-Angiotensin-Aldosterone system blockade in diabetic kidney disease: A critical and contrarian point of view"],"prefix":"10.4103","volume":"27","author":[{"given":"MohamedE","family":"Elrggal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaabanM. S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meguid","family":"El Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/1319-2442.194583-1","doi-asserted-by":"crossref","unstructured":"Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. Am J Kidney Dis; 2016 Oct 16;67(3):S139-58.","DOI":"10.1053\/j.ajkd.2016.02.012"},{"key":"key-10.4103\/1319-2442.194583-2","first-page":"1093","volume-title":"The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus","author":"Valmadrid","year":"2000","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/1319-2442.194583-3","first-page":"225","volume-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-4","first-page":"57","volume-title":"In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria","author":"Perkins","year":"2010","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-5","first-page":"1560","volume-title":"Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?","author":"MacIsaac","year":"2006","journal-title":"Diabetes Care"},{"key":"key-10.4103\/1319-2442.194583-6","first-page":"1036","volume-title":"Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions","author":"Caramori","year":"2003","journal-title":"Diabetes"},{"key":"key-10.4103\/1319-2442.194583-7","first-page":"1993","volume-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"key-10.4103\/1319-2442.194583-8","first-page":"384","volume-title":"Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?","author":"Remuzzi","year":"1990","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-9","first-page":"572","volume-title":"Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury","author":"Remuzzi","year":"1992","journal-title":"Lab Invest"},{"key":"key-10.4103\/1319-2442.194583-10","first-page":"304","volume-title":"Nephrotoxicity of increased glomerular protein traffic","author":"Abbate","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.4103\/1319-2442.194583-11","first-page":"1651","volume-title":"Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation","author":"Bidani","year":"2000","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-12","first-page":"165","volume-title":"Chronic kidney disease","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/1319-2442.194583-13","first-page":"2285","volume-title":"Regression of microalbuminuria in type 1 diabetes","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-14","first-page":"S39","volume-title":"Markers of and risk factors for the development and progression of diabetic kidney disease","author":"Macisaac","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key-10.4103\/1319-2442.194583-15","doi-asserted-by":"crossref","unstructured":"MacIsaac RJ, Ekinci EI, Jerums G. \u2032Progressive diabetic nephropathy. How useful is microalbuminuria? Contra\u2032. Kidney Int 2014; 86:50-7.","DOI":"10.1038\/ki.2014.98"},{"key":"key-10.4103\/1319-2442.194583-16","first-page":"246","volume-title":"Diabetic kidney disease with and without albuminuria","author":"Macisaac","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key-10.4103\/1319-2442.194583-17","first-page":"1089","volume-title":"Albuminuria is not an appropriate therapeutic target in patients with CKD: The con view","author":"Fried","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key-10.4103\/1319-2442.194583-18","first-page":"40","volume-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-19","first-page":"851","volume-title":"Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-20","first-page":"861","volume-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-21","first-page":"907","volume-title":", et al.Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-22","first-page":"1086","volume-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-23","first-page":"547","volume-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"key-10.4103\/1319-2442.194583-24","first-page":"1892","volume-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-25","first-page":"2204","volume-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-26","first-page":"1456","volume-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The Collaborative Study Group","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-27","first-page":"2159","volume-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1319-2442.194583-28","first-page":"2494","volume-title":"Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes","author":"Thomas","year":"2005","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-29","first-page":"370","volume-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors.A meta-analysis of individual patient data?","author":"ACE","year":"2001","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/1319-2442.194583-30","first-page":"2026","volume-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and metaanalysis","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"key-10.4103\/1319-2442.194583-31","first-page":"f5680","volume-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-analysis of randomised controlled trials","author":"Blood","year":"2013","journal-title":"BMJ"},{"key":"key-10.4103\/1319-2442.194583-32","first-page":"3027","volume-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key-10.4103\/1319-2442.194583-33","first-page":"2170","volume-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key-10.4103\/1319-2442.194583-34","first-page":"542","volume-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/1319-2442.194583-35","first-page":"283","volume-title":"Composite endpoints in clinical trials","author":"Ferreira-Gonz\u00e1lez","year":"2008","journal-title":"Rev Esp Cardiol"},{"key":"key-10.4103\/1319-2442.194583-36","first-page":"771","volume-title":"Renal endpoints in renal and cardiovascular randomized clinical trials: Time for a consensus?","author":"Halimi","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"key-10.4103\/1319-2442.194583-37","first-page":"2892","volume-title":"With special reference to trials in the field of arrhythmias and sudden death.Task Force of the Working Group on Arrhythmias of the European Society of Cardiology","author":"The","year":"1994","journal-title":"Circulation"},{"key":"key-10.4103\/1319-2442.194583-38","first-page":"219","volume-title":"Premature termination of clinical trials - Lessons learned","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key-10.4103\/1319-2442.194583-39","first-page":"1575","volume-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","author":"ACCORD","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-40","first-page":"1547","volume-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","author":"ONTARGET","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-41","first-page":"f360","volume-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"key-10.4103\/1319-2442.194583-42","first-page":"e78465","volume-title":"ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: A longitudinal ecological study","author":"Tomlinson","year":"2013","journal-title":"PLoS One"},{"key":"key-10.4103\/1319-2442.194583-43","first-page":"913","volume-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","author":"Suissa","year":"2006","journal-title":"Kidney Int"},{"key":"key-10.4103\/1319-2442.194583-44","first-page":"3977","volume-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.4103\/1319-2442.194583-45","first-page":"255","volume-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: The STOP-ACEi trial","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.4103\/1319-2442.194583-46","first-page":"2350","volume-title":"Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence","author":"Hiremath","year":"2007","journal-title":"Am J Transplant"},{"key":"key-10.4103\/1319-2442.194583-47","first-page":"CD003598","volume-title":"Antihypertensive treatment for kidney transplant recipients","author":"Cross","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/1319-2442.194583-48","first-page":"318","volume-title":"Ramipril versus placebo in kidney transplant patients with proteinuria: A multicentre, double-blind, randomised controlled trial","author":"Knoll","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/1319-2442.194583-49","first-page":"145","volume-title":"Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The Heart Outcomes Prevention Evaluation Study Investigators","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1319-2442.194583-50","first-page":"E2832","volume-title":"Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE Substudy","author":"Svensson","year":"2001","journal-title":"Hypertension"},{"key":"key-10.4103\/1319-2442.194583-51","first-page":"1527","volume-title":"Effects of differrent blood-pressure-lowering regimens on major cardiovascular events: Results of prospectivelydesigned overviews of randomised trials","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"key-10.4103\/1319-2442.194583-52","first-page":"2103","volume-title":", Williamson JD, et al.A randomized trial of intensive versus standard blood-pressure control","author":"SPRINT","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Saudi Journal of Kidney Diseases and Transplantation"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:38:54Z","timestamp":1498376334000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.sjkdt.org\/text.asp?2016\/27\/6\/1103\/194583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"alternative-id":["194583"],"URL":"https:\/\/doi.org\/10.4103\/1319-2442.194583","relation":{},"ISSN":["1319-2442"],"issn-type":[{"value":"1319-2442","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}